To clarify the feasibility of the herpes simplex virus (HSV) vector in expressing the foreign gene in the motor neuron, we inoculated a live attenuated HSV expressing ␤-galactosidase (␤-gal) activity under a latency-associated transcript promoter in the right gastrocnemius muscle of rats. Expression of ␤-gal activity was observed 5 days after inoculation in the bilateral anterior horn cells of the spinal cord that innervates the inoculation muscle. However, the spread of ␤-gal activity was not observed in the inoculation muscle. Without significant pathological changes, the spread of ␤-gal-expressing neurons was observed in the lumbosacral
Introduction
Genetic mutations in a number of inherited central nervous system (CNS) diseases have been identified and these mutations indicate the possibility of gene therapy as one of many therapeutic approaches for these disorders. [1] [2] [3] [4] [5] [6] Somatic gene therapy may also have a role in the treatment of acquired neurological diseases, such as degenerative diseases. In this report, we demonstrate the feasibility of gene delivery to the CNS motor neurons via retrograde axonal transport following intramuscular inoculation of a live attenuated herpes simplex virus (HSV) vector.
HSV is a neurotropic virus and becomes latent in the nervous system after infection. 7, 8 Characteristically, latency-associated transcripts (LAT) are transcribed in neurons infected latently with HSV. 7, 9 Recombinant HSV expressing ␤-galactosidase (␤-gal) has been constructed by inserting the ␤-gal gene into the LAT region and then examined for its expression in the nervous system. 10, 11 Pathogenicity, such as neurovirulence, of a live replication-competent HSV vector [12] [13] [14] has lead to the development of a helper-dependent HSV vector to transfer the foreign genes into the neurons. [15] [16] [17] The helper-dependent vector has little cytotoxic activity but the number of copies introduced is limited to that of the inoculum when spinal cord until 14 days after inoculation with staining concentrated in the anterior horn cells. Ninety percent of the anterior horn motor neurons expressed ␤-gal activity with expression continuing to at least 182 days after inoculation. Thus ␤-gal activity was expressed in the bilateral anterior horn cells at the lumbosacral spinal cord that innervates the inoculated muscle for a long time, possibly a life-long period. This indicates that this recombinant HSV vector system to motor neurons may further improve the understanding and treatment of neurological diseases in motor neurons of the spinal cord. Gene Therapy (2000) 7, 934-941.
used as a vector. However, a replication-competent virus can replicate and increase the number of copies, and lifelong expression of the foreign gene can be expected as long as the latent state continues as reviewed. 7 Keir et al 13 have reported that gene delivery into spinal motor neurons after unilateral inoculation of a live HSV vector at a peripheral muscular site is feasible. ␤-Gal expression was detected in the neurons of the anterior horn up to 28 days after inoculation; however, this expression was detected only in the ipsilateral anterior horn motor neurons. Histological studies showed mild lesions in the anterior horn that progressed from 3 days up to 28 days after inoculation. 13 In our previous report, 18 we selected the most attenuated strain (HF) to mice from our HSV-1 library and constructed an HSV-1 (␤H1) vector expressing ␤-gal activity under the LAT promoter. The ␤-gal gene was inserted between the LAT regions comprising of sequences 5131-6381 and 6775-8275, forming the chimeric plasmid pUC-LAT-␤-gal. ␤H1 was isolated by cotransfection with DNA of the HF strain and pUC-LAT-␤-gal and a single copy of the ␤-gal gene was retained and stable in the ␤H1 genome. The plaque size of ␤H1 was smaller than that of the parent HF strain and the virus yield in Vero cell cultures was one tenth lower in the ␤H1 strain than in the parent HF strain. In contrast to the parent strain, the pathogenicity of ␤H1 in mice was lost, even with intracerebral injection of the virus. ␤-Gal activity, expressed by ␤H1, was observed in the neurons of the sensory ganglia innervating the inoculation site for at least 45 days after subcutaneous injection without causing tissue destruc-tion or inflammation. Behavioral changes were not noted in rats infected with the ␤H1 strain during the observation period in contrast to infection with the parent HF strain and the wild 7401H strain. We introduced the foreign gene into the spinal cord motor neurons of the rat by inoculating ␤H1 in the muscle and evaluated the potential use of this live HSV as a vector for the understanding and treatment of neurological diseases affecting motor neurons.
Results

Animal health
No behavioral changes nor any illness was observed after a live attenuated HSV-1, ␤H1 strain, was inoculated into the right gastrocnemius muscle of Wistar rats. Good weight gain, along with the absence of any inflammatory responses, was observed in all rats inoculated with ␤H1 strain and phosphate buffered saline (PBS). Rats inoculated with the parent HF strain developed light right or bilateral posterior limb paralysis and recovered. Rats inoculated with the 7401H strain developed bilateral posterior limb paralysis on day 4 and then progressed to death.
The histological examination of the spinal cord following intramuscular inoculation of recombinant HSV expressing ␤-gal under the LAT promoter Histological sections from the spinal cord, brain, and the gastrocnemius muscles were taken from rats at 12 h and 1-182 days after inoculation. The cryostat sections were stained for ␤-gal activity. Histochemical analysis of these sections demonstrated that the inoculation of ␤H1 in the right gastrocnemius muscle resulted in both a high-level and long-term ␤-gal expression in the bilateral anterior horn motor neurons at the innervating lumbosacral level of the spinal cord. No significant pathological changes were observed on the days examined (Figures 1 and 2 ). ␤-Gal activity in rat lumbar (L) 1 and L4 of the spinal cord was localized in the anterior horn motor neurons 182 days after inoculation. Staining of the entire cytoplasm with X-gal was visualized at higher magnification in Figure 1a and b. It was demonstrated in the L5 level of the spinal cord on day 15 after inoculation that ␤-gal activity was localized on the both sides of the anterior horn cells (Figure 2a ). ␤-Gal activity was concentrated in the anterior horn cells in L5 of the spinal cord on 28 days after inoculation (Figure 2b) . Similarly, 182 days after inoculation in L5, ␤-gal expression was concentrated in clusters in the cytoplasm of the anterior horn motor neurons (Figure 1c ). ␤-Gal expression was not observed in sequential sections at the thoracic and lower sacral levels. There were no apparent histological changes such as hemorrhagic necrosis, inflammatory infiltration, neuronophagia, patchy neuronal loss, gliosis or demyelination in the spinal cord. Figure 2c shows the spinal cords from rats inoculated in the right gastrocnemius muscle with the parent HF strain on day 28 after staining with X-gal; any ␤-gal staining was not observed. There was no ␤-gal staining in the anterior horn cells from rats inoculated with PBS, the parent HF strain, or the wild 7401H strain even with longer incubation in staining solution (data not shown).
To examine the spread of HSV infection after its inocuGene Therapy lation in the right gastrocnemius muscle, we used ␤H1 and a wild 7401H strain for infection to detect the expression of the HSV antigen in the spinal cord. Figure  3 illustrates the immunoperoxidase staining against the HSV antigen in the spinal cord of the rat 5 days after inoculation of wild 7401H HSV into the right gastrocnemius muscle. Both sides of the anterior horn motor neurons were stained with anti-HSV serum. Rats inoculated with wild 7401H HSV developed posterior limb paralysis on day 5 and died. The appearance of anti-HSV staining in the anterior horn cells in the spinal cord was essentially similar between ␤H1 and 7401H strain but the staining with ␤H1 infection was weaker than that with the wild 7401H infection. The time-course of the appearance of anti-HSV staining in the anterior horn cells was consistent with that of ␤-gal staining (data not shown).
The progression of the ␤-gal activity within the rat spinal cord and the other sites Apparent divergence in the expression of ␤-gal activity within the anterior horn motor neurons was observed. Hence, the strength of ␤-gal activity was classified into three grades; strong, weak, and negative expression. The progression of ␤-gal activity is indicated in Figure 4 . ␤-Gal activity became detectable in the anterior horn motor neurons at L3 to L5 of the spinal cord corresponding with the innervation of the gastrocnemius muscle on day 5 (data not shown). This is consistent with the appearance of the HSV antigen in the anterior horn motor neurons. The distribution then continued to spread from 5 days after inoculation with no spreading after 14 days. This suggested that ␤H1 growth might end between 5 and 14 days after infection. Thereafter ␤H1 became latent in the anterior horn cells. Subsequently, ␤-gal activity was predominantly observed in the bilateral anterior horn motor neurons up to 182 days after inoculation (Figures 1a-c and 4). At this time the distribution of ␤-gal expressing neurons ranged from L1 to sacral (S) 1 in the spinal cord as illustrated in Figure 4 . Expression of ␤-gal including strong and weak expression in three grades was observed in about 90% of the anterior horn motor neurons at 182 days after inoculation as shown in Table 1 . Although no statistical difference in the ratio of strongly and weakly positive cells was present, strong expression seemed to dominate in the L5 level. Except for some small patchy staining with ␤-gal in the muscle, the spread of ␤-gal activity was not observed at the inoculation site or its surrounding area of muscle, nor at any other level of the spinal cord or any other part of the CNS (Figure 4 ).
Discussion
A newly developed HSV vector was successfully introduced into the anterior horn motor neurons of the spinal cord where ␤-gal activity was observed without apparent tissue destruction or inflammation. The expression of ␤-gal activity was recognized in 90% of the motor neurons and lasted for over 182 days, even though this HSV vector had an attenuated nature. This gene expression occurred under the control of the LAT promoter during the latent phase of this virus. Like HSV, known to become latent in the sensory ganglia, [19] [20] [21] [22] [23] this chimeric HSV-1 may enter the latent phase in the anterior horn motor neurons with expression of ␤-gal activity after transport from the skeletal muscle. The spread of ␤-gal activity in the spinal cord did not further progress later than 14 days after inoculation. This was consistent with the spread observed in the sensory or trigeminal ganglia (unpublished data).
Specificity of ␤-gal staining in the spinal cord of rats infected with ␤H1 was confirmed by the absence of its staining in the anterior horn motor neurons of the spinal cord of rats inoculated with PBS, the parent HF strain, or the wild 7401H strain. We could not observe any ␤-gal staining in the anterior horn motor neurons on days 0.5, 1, 3, 5, and 7 after inoculation with PBS, the parent HF strain, or the wild 7401H strain or on days 15 and 28 after inoculation with PBS and the parent HF strain. Although ␤-gal expression was observed in the lumbosacral levels of the spinal cord of rats inoculated with ␤H1, it was not observed in their sequential sections at the thoracic levels under the same staining condition. The HSV antigen was observed in the bilateral anterior horn motor neurons of the spinal cord of rats infected with the wild 7401H strain as shown in Figure 3 . The HSV antigen was also observed in the anterior horn motor neurons of rats inoculated with ␤H1 but the density of the immunostaining was lower in the ␤H1-infected spinal cord than in the 7401H-infected spinal cord (data not shown). This may correspond to the 10 times lower virus yield in ␤H1-infected cultures than parent HF-infected cultures and this may be reflected on the poor growth of ␤H1 in the spinal cord.
Gene Therapy HSV may be incorporated from the nerve end in the muscle and transported to the anterior horn motor neurons or the sensory neurons by retrograde axonal transport.
12,24-27 On day 5 after inoculation, ␤-gal activity was observed in the spinal cord at the level innervating the muscle. This expression was consistent with the results of immunostaining of the HSV antigen in the anterior horn motor neurons. Thus the appearance of the HSV antigen and ␤-gal activity in the bilateral anterior motor neurons is consistent with the detailed study on the spread of HSV infection in the spinal cord as reported by Ugolini. 27 Interestingly no histological changes nor spread of ␤-gal expression was detected at the inoculation site or the surrounding area throughout this observation period except for some small patchy staining with ␤-gal in the muscle, indicating no detectable replication or inflammation at the inoculation site. Therefore HSV may have been incorporated at the neuromuscular junction or the nerve ending of the sensory neurons by retrograde axonal transport and transported to the anterior horn cells. The speed of axonal transport is known to be 46-400 mm/day. [28] [29] [30] Therefore, it may be reasonable that the transport and spread in the spinal cord may be via the axon from the nerve ending in the muscle to the motor neurons and then transneuronal spread from anterior horn motor neurons to the other side of neuronal cells in the spinal cord. 31 Therefore, ␤H1 may have traveled from the inoculation site to the anterior horn motor neurons without local replication or transneuronal spread to other neurons in the wide range of the spinal cord.
Previous studies have reported the presence of inflammation in the organ expressing the recombinant gene following inoculation with replication-defective adenovirus 5, [32] [33] [34] and replication-defective HSV-1. 35 The cause of these changes is not clear, but it is suspected to result partly from a direct toxicity of the virus, as well as from an immune response against the viral proteins. 5, 35 By contrast, in spite of the spread of infection, as assessed with ␤-gal expression and the expression of the HSV antigen by our replication-competent HSV vector, tissue destruction, inflammation of the spinal cord, or loss of neurons was not noted during any examination period in this study. This may be one of the suitable characteristics of this vector system.
It has been reported that the foreign gene is transiently expressed in motor neurons following inoculation with replication-defective adenovirus and replication-defective HSV-1. On the other hand, Lachmann and Efstathiou 14 reported that the long-term expression of ␤-gal was observed in a wide variety of neurons in some of 939 Strongly positive cells and weakly positive cells indicate the two grades of positive cell as shown in Figure 2 . The percentage of ␤-gal expressing cells was determined by an average of five sections from L1 to S1 of the rat spinal cord. L, lumbar; S, sacral.
the survivor mice when virulent HSV-1 expressing LATdriven ␤-gal was inoculated into the pinna of the left ear. They observed bilateral ␤-gal activity in both the anterior and posterior horn neurons of latently infected mice sampled at 130 days after infection as a part of a widespread range of ␤-gal expressing areas. The motor neurons utilize the LAT promoter for expression of the foreign gene. 13, 14 Thus the replication-competent HSV vector can deliver the foreign gene into the anterior horn motor neurons via muscle. However, this HSV vector induced inflammation and some of the mice died during their experiment because of the virulence of the virus. Furthermore the HSV antigen is observed in the bilateral anterior motor neurons after inoculation of virulent HSV into the peripheral nerve. 27 These reports have suggested that the foreign gene can be expressed for a long time in the bilateral anterior horn motor neurons under the LAT promoter after intramuscular inoculation of a live HSV vector.
Our study demonstrates the feasibility of gene transfer to selected motor neuronal cell populations by inoculating a live attenuated HSV vector into the skeletal muscle. Concerning the efficiency of gene delivery in the anterior horn motor neurons, 90% of them expressed ␤-gal in a wide range of the spinal cord by our replication-competent HSV vector as shown in Figure 4 and Table 1 . Expression continued for more than 182 days after inoculation. Therefore, the expression of ␤-gal activity is widespread and long-term without significant pathological changes. From these results, when a muscle in the upper extremity is inoculated with this vector, the whole range of the spinal cord may be covered by expression of ␤-gal in the anterior horn motor neurons. This may be another advantage of this vector system.
Replication-defective adenovirus and replication-defective HSV-1 have both advantages and disadvantages as vectors for the gene therapy of motor neuron diseases. Our live HSV vector has little pathogenicity and in addition to the attenuated nature, the widespread and long-term expression of the foreign gene would be an advantage of this HSV vector. Therefore this HSV vector system may be suitable as a gene delivery vector in the motor neurons of the spinal cord.
Previous studies have demonstrated that the mutations in the gene encoding the oxygen radical metabolizing enzyme copper-zinc superoxide dismutase (SOD-1) are 39 suggesting that the sites of recombinant HSV-1 expression that we demonstrated in this study may be satisfactory for correcting the defect in FALS. Similar strategies using intramuscular injection of a live attenuated HSV-1 vector may be useful for the understanding and treatment of other inherited and acquired neurodegenerative disorders.
Materials and methods
Preparation of a live attenuated HSV-1, ␤H1 A live attenuated HSV-1, ␤H1, was prepared as described previously. 18, 40 Briefly, ␤H1 was propagated in the Vero cell culture and harvested after three cycles of freezing and thawing of the culture. The culture medium was centrifuged at 3000 r.p.m. for 20 min at 4°C and the supernatant was stocked at −85°C until use. The virus titer was determined with the overlay containing 5-bromo-4-chloro-3-indolyl-␤-d-galactoside (X-gal). No revertant virus was detected even in low dilution of the virus stock. The parent HF strain and the wild 7401 strain were similarly prepared.
Animals
Adult male Wistar rats (8-week-old) were used for intramuscular inoculations. Virus inoculation and behavioral experiments were done in the infection room (specific pathogen free) of the Laboratory Animal Center (Toyama Medical and Pharmaceutical University). Procedures involving animals and their care were conducted conforming with the animal experimentation guidelines of Toyama Medical and Pharmaceutical University.
Virus injections and histological processing of tissue
For intramuscular inoculation rats were anesthetized with pentobarbital sodium (40 mg/kg, intraperitoneal injection). Animals were then inoculated with 1.0 × 10 7 p.f.u. per dose of ␤H1 in 80-100 l into the right gastrocnemius muscle under direct inspection without administration into the surrounding tissues, such as blood vessels or nerves. Inoculation was made using 1 ml syringe and a 26-gauge needle over a period of a few minutes and the syringe was left in place for an additional few minutes before withdrawal. As a control PBS was inoculated instead of ␤H1. A wild-type 7401H strain was also inoculated in order to compare the pathogenicity and to analyze the spread of viral infection in the spine. A minimum of three animals were anesthetized by ether, killed on days 0.5, 1, 3, 5, 7, 14, 15, 28, 72, and 182 after inoculation, and perfused with cold PBS followed by 4% paraformaldehyde. Tissues were removed and fixed in 4% paraformaldehyde for 1-4 h at 4°C. Tissues were cut smaller than 1 cm 3 and placed in 30% sucrose overnight. 41 Finally they were frozen in Tissue-Tek OCT embedding compound (Sakura Finetechnical, Tokyo, Japan). Fourteen micron horizontal sections of the spinal cord, 50 m coronal sections of brain and 14 m sagittal sections of gastrocnemius muscles were cut on a Frigocut 2800N Cryostat (Finetec, Tokyo, Japan). The sections of the spinal cord were taken from cervical 1 to sacral 3, the brain sections were taken from the caudal part of the olfactory bulb through to the rostral of the entorhinal cortex. The muscle sections were taken from whole samples. The sections were reacted with X-gal 42 and then subsequently stained with neutral red.
Immunohistochemistry
An immunohistochemical study was made to detect the localization of the HSV antigen in the spinal cord. The cryostat sections at a thickness of 4 m were obtained from the lumbal segment of the spinal cord and were fixed with 100% acetone at 4°C for 10 min after air-drying. The sections were washed with PBS (0.05 m, pH 7.6). The slides were incubated overnight at 4°C with the primary antibody (rabbit polyclonal anti-Herpes simplex virus type 1, Dako Laboratories, Glostrup, Denmark, 1:800 dilution). The bound antibody was detected by the peroxidase labelled polymer conjugated to goat anti-rabbit immunoglobulin (Dako Laboratories) with diaminobenzidine tetrahydrochloride (Sigma, St Louis, MO, USA) as the chromogenic substrate.
Analysis
Sections were examined using the Olympus AX80T (Olympus, Tokyo, Japan) microscope and the expression of ␤-galactosidase was observed. The expression of ␤-gal activity was classified into three grades; strong, weak and negative expression as indicated in Figure 4 . To improve accuracy, sections were examined by more than one individual.
